Dr. Tony Holohan:

Yes. In broad terms for screening programmes, and as a point of principle, that has two dimensions to it. One is what the evidence says, in general terms, around the performance of tests, but then there is also the question of the risks and benefits that arise in a particular country or a particular setting. Ultimately, the costs and expenditures that accrue here will be difficult, so the cost and benefit of a screening programme, even if the technology is the same, can be different in different populations.